In early February 2026, the U.S. District Court for the District of Delaware denied Moderna’s bid for summary judgment in a ...

CAMBRIDGE, MA / ACCESS Newswire / September 16, 2025 / Moderna, Inc. (NASDAQ:MRNA) today announced positive preliminary immunogenicity data for the 2025-2026 formula of Spikevax®, which targets the LP ...

Moderna has early in-human data showing its next-generation COVID-19 vaccine, mNEXSPIKE, has the potential to offer strong immune protection against the latest rapidly spreading SARS-CoV-2 virus.

Moderna said on Tuesday its updated COVID-19 vaccine formulation elicited a strong immune response in all adults aged 65 and older, as well as in individuals aged 12 to 64 with at least one underlying ...

RUNNEMEDE, New Jersey (WPVI) -- This week, Pfizer asked the FDA for authorization of a second COVID-19 booster shot for senior citizens to fight waning immunity. On Thursday, Moderna asked for that ...

LOS ANGELES -- The COVID-19 vaccines made by Pfizer and Moderna both require two doses to be administered, several weeks apart, for them to be fully effective. But there has been some scientific ...

An expert panel of the EU drug regulator, the European Medicines Agency (EMA), endorsed seven new medicines for approval this week, including a cancer drug from ImmunityBio (IBRX) and Moderna's (MRNA) ...

Preliminary analysis showed the 2025-2026 formula of mNEXSPIKE generated greater than a 16-fold increase in LP.8.1-neutralizing antibodies across age groups Both of Moderna’s COVID-19 vaccines for the ...